Feed status
4 parsed articles
Last update: Not fetched
2026-03-27
Holly Webster
Nature Reviews Rheumatology, Published online: 27 March 2026; doi:10.1038/s41584-026-01370-w Preclinical findings indicate that vamifeport, an oral ferroportin inhibitor, could be used as an adjunct therapy for lupus nephritis.
2026-03-23
Holly Webster
Nature Reviews Rheumatology, Published online: 23 March 2026; doi:10.1038/s41584-026-01368-4 Findings suggest that changes in serum IgG4 levels over time are predictive of IgG4-related disease relapse and might identify patients amenable to preventative treatment.
2026-03-02
Lilla Gunkl-Tóth, Iain B. McInnes, György Nagy
Nature Reviews Rheumatology, Published online: 02 March 2026; doi:10.1038/s41584-026-01354-w In this Perspective, the authors discuss how integrating difficult-to-treat into the treat-to-target strategy could improve outcomes for those patients with rheumatoid arthritis who do not follow the standard treat-to-target trajectory. The proposed strategy is aimed at providing a more personalized approach to disease management for those patients with difficult-to-treat disease.
2026-02-25
Sarah Sisbot
Nature Reviews Rheumatology, Published online: 25 February 2026; doi:10.1038/s41584-026-01364-8 Drawing on my contrasting experiences as a patient in oncology and rheumatology, I have seen how the lack of precision-based diagnostics and meaningful endpoints limits progress in rheumatic disease. I believe biologically grounded classification systems and greater patient involvement are essential for more effective and responsive care.